Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial


      Lipoprotein subclass analyses may facilitate coronary heart disease (CHD) risk stratification and provide insight into the cardioprotective benefits of statins (3-hydroxymethylglutaryl-coenzyme A reductase inhibitors). This study evaluated the influence of pravastatin on lipoprotein subclass profiles to determine whether subjects with predominantly large LDL (LDL size >20.5 nm) or small LDL (LDL size ≤20.5 nm) at baseline differ in responsiveness to drug treatment. Frozen plasma specimens were analyzed from a subset of participants in the Pravastatin Limitation of Atherosclerosis in the Coronaries (PLAC-I) trial at baseline and after treatment for 6 months with pravastatin (n=154) or placebo (n=138). Lipids were measured by standard chemical methods and lipoprotein subclasses by nuclear magnetic resonance (NMR) spectroscopy. Pravastatin-induced changes in lipid levels were similar in subjects with large or small LDL at baseline. Levels of the most abundant LDL subclass were preferentially lowered by pravastatin, resulting in an increase in average LDL size for those with a predominance of small LDL. High-risk CHD subjects with small LDL particles gain at least as much pharmacological benefit from pravastatin as those with large LDL, as evidenced by reductions in the numbers of total and small LDL particles, and increases in average LDL and HDL particle size.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rosenson R.S.
        • Tangney C.C.
        Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction.
        J. Am. Med. Assoc. 1998; 279: 1643-1650
        • Freedman D.S.
        • Otvos J.D.
        • Jeyarajah E.J.
        • Barboriak J.J.
        • Anderson A.F.
        • Walker J.A.
        Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1046-1053
        • Krauss R.M.
        Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk.
        Curr. Opin. Lipidol. 1994; 5: 339-349
        • Austin M.A.
        • Hokanson J.E.
        • Brunzell J.D.
        Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance.
        Curr. Opin. Lipidol. 1994; 5: 395-403
        • Cheung M.C.
        • Austin M.A.
        • Moulin P.
        • Wolf A.C.
        • Cryer D.
        • Knopp R.H.
        Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
        Atherosclerosis. 1993; 102: 107-119
        • Franceschini G.
        • Cassinotti M.
        • Vecchio G.
        • Gianfranceschi G.
        • Pazzucconi F.
        • Murakami T.
        • et al.
        Pravastatin effectively lowers LDL cholesterol in familial combines hyperlipidemia without changing LDL subclass pattern.
        Arterioscler. Thromb. 1994; 14: 1569-1575
        • Zambon S.
        • Cortella A.
        • Sartore G.
        • Baldo-Enzi G.
        • Manzato E.
        • Crepaldi G.
        Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size.
        Eur. J. Clin. Pharmacol. 1994; 46: 221-224
        • Kontopoulos A.G.
        • Athyros V.G.
        • Papageorgiou A.A.
        • Hatzikonstandinou H.A.
        • Mayroudi M.C.
        • Boudoulas H.
        Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
        Coron. Artery. Dis. 1996; 7: 843-850
        • Pitt B.
        • Mancini G.B.J.
        • Ellis S.G.
        • Rosman H.S.
        • Park J.S.
        • McGovern M.E.
        Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events.
        J. Am. Coll. Cardiol. 1995; 26: 1133-1139
        • Otvos J.D.
        • Jeyarajah E.J.
        • Bennett D.W.
        • Krauss R.M.
        Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement.
        Clin. Chem. 1992; 38: 1632-1638
        • Otvos J.D.
        Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.
        in: Rifai N. Warnick G.R. Dominiczak M.H. Handbook of Lipoprotein Testing. 2nd ed. AACC Press, Washington, DC2000: 609-623
        • Rumsey S.C.
        • Galeano N.F.
        • Arad Y.
        • Deckelbaum R.J.
        Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins.
        J. Lipid Res. 1992; 33: 1551-1561
        • McNamara J.R.
        • Small D.M.
        • Li Z.
        • Schaefer E.J.
        Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B.
        J. Lipid Res. 1996; 37: 1924-1935
        • Grundy S.M.
        • Vega G.L.
        • Otvos J.D.
        • Rainwater D.L.
        • Cohen J.C.
        Hepatic lipase influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence.
        J. Lipid Res. 1999; 40: 229-234
        • Austin M.A.
        • Bleslow J.L.
        • Hennekens C.H.
        • Buring J.E.
        • Willett W.C.
        • Krauss R.M.
        Low-density lipoprotein subclass patterns and risk of myocardial infarction.
        J. Am. Med. Assoc. 1987; 260: 1917-1921
        • Austin M.A.
        • King M.-C.
        • Vrinizan K.M.
        • Krauss R.M.
        Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease.
        Circulation. 1990; 82: 495-506
        • Rudel L.L.
        • Pitts L.L.
        • Nelson C.A.
        Characterization of plasma low density lipoproteins of nonhuman primates fed dietary cholesterol.
        J. Lipid Res. 1977; 18: 211-222
        • Harris R.J.
        A Primer of Multivariate Statistics. Academic Press, New York1975: 67-92
        • Stampfer M.J.
        • Krauss R.M.
        • Blanche P.J.
        • Holl L.G.
        • Sacks F.M.
        • Hennekens C.H.
        A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction.
        J. Am. Med. Assoc. 1996; 276: 882-888
        • Gardner C.D.
        • Fortmann S.P.
        • Krauss R.M.
        Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women.
        J. Am. Med. Assoc. 1996; 276: 875-881
        • Campos H.
        • Roederer G.O.
        • Lussier-Cacan S.
        • Davignon J.
        • Krauss R.M.
        Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1043-1048
        • Lamarche B.
        • Tchernof A.
        • Moorjani S.
        • Cantin B.
        • Dagenais G.R.
        • Lupien P.J.
        • et al.
        Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men.
        Circulation. 1997; 95: 69-75
        • de Graaf J.
        • Hak Lemmers H.L.
        • Hectors M.P.
        • Demacker P.N.M.
        • Hendriks J.C.
        • Stalenhoef A.F.
        Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
        Arterioscler. Thromb. Vasc. Biol. 1991; 11: 298-306
        • Hurt-Camejo E.
        • Olsson U.
        • Wiklund O.
        • Bonders G.
        • Camejo G.
        Cellular consequences of the associations of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis.
        Arterioscler. Thromb. Vasc. Biol. 1997; 17: 1011-1017
        • Haskell W.L.
        • Alderman E.L.
        • Fair J.M.
        • Maron D.J.
        • Mackey S.F.
        • Superko H.R.
        • et al.
        Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).
        Circulation. 1994; 89: 975-990
        • Krauss R.M.
        • Lindgren F.T.
        • Williams P.T.
        • Kelsey S.F.
        • Brensike J.
        • Vranizan K.
        • et al.
        Intermediate-density lipoproteins and progression of coronary disease in hypercholesterolaemic men.
        Lancet. 1987; 2: 62-66
        • Mack W.J.
        • Krauss R.M.
        • Hodis H.N.
        Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression.
        Arterioscler. Thromb. Vasc. Biol. 1996; 16: 697-704
        • Phillips N.R.
        • Waters D.
        • Havel R.J.
        Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events.
        Circulation. 1993; 88: 2762-2770
        • Blankenhorn D.H.
        • Alaupovic P.
        • Wickham E.
        • Chin H.P.
        • Azen S.P.
        Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors.
        Circulation. 1990; 81: 470-476
        • Superko H.R.
        Did grandma give you heart disease? The new battle against coronary artery disease.
        Am. J. Cardiol.. 1998; 82: 34Q-46Q
        • Bredie S.J.
        • deBruin T.W.
        • Demacker P.N.
        • Kastelein J.J.
        • Stalenhoef A.F.
        Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
        Am. J. Cardiol. 1995; 75: 348-353
        • Nestel P.
        • Simons L.
        • Barter P.
        • Clifton P.
        • Colquhoun D.
        • Hamilton-Craig I.
        • et al.
        A comparative study of efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein (a) and insulin.
        Atherosclerosis. 1997; 129: 231-239
        • Superko H.R.
        • Krauss R.M.
        • DiRicco C.
        Effect of fluvastatin on low-density lipoprotein peak particle diameter.
        Am. J. Cardiol. 1997; 80: 78-81
        • Johansson J.
        • Carlson L.A.
        • Landou C.
        • Hamsten A.
        High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients.
        Arterioscler. Thromb. 1991; 11: 174-182
        • Cheung M.C.
        • Brown B.G.
        • Wolf A.C.
        • Albers J.J.
        Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease.
        J. Lipid Res. 1991; 32: 383-394
        • Shepherd J.
        • Cobb S.M.
        • Ford I.
        • Isles C.G.
        • Lorimer A.R.
        • MacFarlane P.W.
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        New Engl. J. Med. 1995; 333: 1301-1307
      1. Air Force/Texas Coronary Atherosclerosis Prevention Study. Presented at the 70th Scientific Sessions of the American Heart Association on November 12, 1998.

        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        New Engl. J. Med. 1996; 335: 1001-1009
        • Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        New Engl. J. Med. 1998; 339: 1349-1357
        • Scandinavian Simvastatin Survival Study Group
        Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1995; 345: 1274-1275